{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":17,"youtube":11,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04722146\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MajesTEC-2","nct_id":"NCT04722146","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=majestec-2-nct04722146. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MajesTEC-2","arms":[{"description":"Participants will receive teclistamab plus daratumumab plus pomalidomide.","label":"Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 21-day cycles.","label":"Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles)","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab plus nirogacestat.","label":"Treatment Regimen C: Teclistamab + Nirogacestat","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab plus lenalidomide.","label":"Treatment Regimen D: Teclistamab + Lenalidomide","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab plus daratumumab plus lenalidomide.","label":"Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 28-day cycles.","label":"Treatment Regimen F: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-10-13","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":140,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Teclistamab","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Pomalidomide","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Nirogacestat","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-10-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Incidence of Adverse Events (AEs)","timeFrame":"Up to 2 year and 5 months"},{"measure":"Number of Participants with AEs by Severity","timeFrame":"Up to 2 year and 5 months"},{"measure":"Number of Participants with Abnormalities in Laboratory Values","timeFrame":"Up to 2 year and 5 months"},{"measure":"Number of Participants with Dose-Limiting Toxicity (DLT)","timeFrame":"Up to Cycle 2 Day 21 (each cycle is of 28 days for Treatment Regimen A and 21 days for Treatment Regimen B)"}],"references":[],"start_date":{"date":"2021-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04722146"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/majestec-2-nct04722146"}